Screening people with Alzheimer's disease for possible future studies
Checks whether adults with Alzheimer's disease may qualify for later research studies.
Plain-language title generated from the registry record
Registry title: Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Key facts
- Where
- Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku, Mie, Okayama, Osaka, Tokyo, and Yamagata, JapanSee the 28 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT07177352, who can take part
Where in Japan
- National Center for Geriatrics and GerontologyAichi, JapanTaking people
- Brain Attack Center Ota Memorial HospitalHiroshima, JapanNo longer taking part
- National Hospital Organization Hiroshima-Nishi Medical CenterHiroshima, JapanNo longer taking part
- Kobe University HospitalHyōgo, JapanTaking people
- Kagawa University HospitalKagawa, JapanNo longer taking part
- Yokohama City Minato Red Cross HospitalKanagawa, JapanTaking people
- Kochi Medical School HospitalKochi, JapanNo longer taking part
- Kyoto University HospitalKyoto, JapanNo longer taking part
- National Hospital Organization Utano National HospitalKyoto, JapanNo longer taking part
- Mishuku HospitalMeguro-Ku, JapanNo longer taking part
- Mie University HospitalMie, JapanNo longer taking part
- Okayama City HospitalOkayama, JapanNo longer taking part
- Rijikai Medical Corporation Katayama Medical ClinicOkayama, JapanNo longer taking part
- Iwata Neurosurgery ClinicOsaka, JapanTaking people
- Medical Corporation Heishinkai OCROM ClinicOsaka, JapanTaking people
- Kotobuki Social Medical Corporation Tominaga ClinicOsaka, JapanNo longer taking part
- Clinical Research Hospital TokyoTokyo, JapanTaking people
- Higashi Shinjuku ClinicTokyo, JapanTaking people
- Medical Corporation Asbo Tokyo Asbo ClinicTokyo, JapanTaking people
- The University of Tokyo HospitalTokyo, JapanTaking people
- Tokyo Medical University HospitalTokyo, JapanTaking people
- Tokyo Metropolitan Institute for Geriatrics and GerontologyTokyo, JapanTaking people
- Federation of National Public Service Personnel Mutual Aid Associations Tachikawa HospitalTokyo, JapanNo longer taking part
- Keio University HospitalTokyo, JapanNo longer taking part
- Memory Clinic OchanomizuTokyo, JapanNo longer taking part
- National Center of Neurology and PsychiatryTokyo, JapanNo longer taking part
- P-One ClinicTokyo, JapanNo longer taking part
- Yamagata Tokusyukai HospitalYamagata, JapanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07177352
- Record updated
- 19 October 2026
- Original description
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.Read full original descriptionShow less
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Inclusion: Ability and willingness to participate in an interventional clinical study, including meeting key eligibility criteria of linked interventional Roche AD studies (e.g., specific age ranges); Ability and willingness to receive information about potential eligibility in an associated interventional Roche AD study.
Exclusion: For participants with a clinical diagnosis of MCI or mild AD: Previous AD diagnosis based on biomarker confirmation with an approved or validated rule in method (e.g., amyloid PET or cerebrospinal fluid, blood biomarker) is exclusionary; Dependency in basic activities of daily living (bADLs) due to cognitive impairment; Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted); Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD; History of severe, clinically significant central nervous system trauma; Any serious medical condition that precludes a participant's safe participation and completion of a clinical study.